Trial Profile
A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of Rotigotine on Sleep Efficiency in Patients With Advanced Parkinson's Disease.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2014
Price :
$35
*
At a glance
- Drugs Rotigotine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms REFRESH-PD
- Sponsors UCB Pharma SA
- 26 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Apr 2012 Planned end date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 14 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.